 Hello everybody and welcome once again to San Francisco, California, and the Kidney Cancer Association's continuing coverage of the 2012 genitourinary cancer symposium jointly sponsored by ASCO, the American Society of Clinical Oncology, Astro, the American Society for Radiation Oncology, and SUO, the Society of Urologic Oncology. In tomorrow's news, the experts are saying the current reality in renal cancer is the therapeutic choice of a particular agent is made without the identification of a direct target. Hence, according to Oka Vashapiron, MD, the targeted therapy remains empiric. We'll have news of this and other items of interest throughout the day on Friday, so be sure to join us right here. For continuing updates and more coverage, point your web browser to kidneycancer.org and look in the press room section where you'll find the complete list of abstracts from the 2012 genitourinary cancer symposium. Wishing you good health, I'm Bill Bro.